MORE - Forbes.com: " two factors that should help Tysabri are that no patients taking just Tysabri came down with PML, and that existing drugs to fight multiple sclerosis don%u2019t work for 25% of MS patients. For those 100,000 or so patients in the U.S., Kam says Tysabri can greatly improve their quality of life.
These facts, according to Kam, mean that there is no good reason to withhold Tysabri from this group of patients. He says the U.S. Food and Drug Administration will use this as their justification for returning Tysabri to the market as a monotherapy with a big 'black box' warning about the risk of PML on the label.
%u201CWall Street is beginning to agree that Tysabri will return, but Merril Lynch and Citibank both recently reiterated their sell recommendations, both citing their belief that Tysabri will be hard to sell to physicians and MS patients until the risks of PML are better understood,"
